The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

The U.S. Food and Drug Administration (FDA) has approved Sanofi’s (NASDAQ:SNY) meningococcal vaccine MenQuadfi for infants as ...

French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants ...

(RTTNews) - Sanofi said that the U.S. Food and Drug Administration has approved a Biologics License Application for MenQuadfi Meningococcal Conjugate Vaccine for the prevention of invasive ...

Dublin, June 12, 2020 (GLOBE NEWSWIRE) -- The "MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) Drug Overview" report has been added to ResearchAndMarkets.com's offering.

European Commission approves MenQuadfi ®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older EC approval based on robust data from seven ...

The U.S. Food and Drug Administration (FDA) has approved Sanofi’s (NASDAQ:SNY) meningococcal vaccine MenQuadfi for infants as young as six weeks, expanding its previous label indicated for ...

The FDA has recently approved MenQuadfi, a meningococcal conjugate vaccine that protects against serogroups A, C, Y and W. The approval is for patients aged 2 years and older, according to a press ...